Photo Credit: JMrocek
The following is a summary of “Clinical efficacy of intracavernous injection of platelet lysate for erectile dysfunction,” published in the October 2024 issue of Urology by Chang et al.
Platelet-rich plasma (PRP) is an emerging treatment for erectile dysfunction (ED) that enhances tissue repair and regeneration, representing a promising therapeutic approach for patients with ED.
Researchers conducted a retrospective study to analyze the efficacy of intracavernous injections of platelet lysate (PL), a PRP derivative, in improving erectile function in patients with ED.
They enrolled 26 patients aged 35 to 70 years (mean age 51.6 ± 11.3 years) with ED lasting over 6 months and an International Index of Erectile Function-5 (IIEF-5) score of 21 or less. Participants received autologous PL injections intracavernously every 2 weeks for a total of 5 treatments. They assessed Erection Hardness Score (EHS) and IIEF-5 biweekly for 16 weeks and performed penile Doppler ultrasounds pre- and post-treatment to measure peak systolic velocity (PSV) and resistance index (RI).
The results showed that before treatment, the mean Erection Hardness Score (EHS) was 2.15 ± 0.88 and the IIEF-5 was 10.92 ± 5.28. Post-treatment, EHS increased to 3.15 ± 0.83 (P < 0.05) and IIEF-5 to 17.23 ± 5.26 (P< 0.05). Penile Doppler ultrasound showed significant increases in PSV and RI after treatment, with a statistically significant rise in RI.
The study concluded that intracavernous injections of PL significantly improved erectile function in patients with moderate ED and were safe with minimal adverse effects.
Source: bmcurol.biomedcentral.com/articles/10.1186/s12894-024-01633-2
